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Drug-induced lupus is a side effect of deliberate ingestion of various medications, but its etiology,
underlying mechanisms, and pathogenesis are puzzling. In vivo metabolic transformation of lupus-
inducing drugs to reactive products explains how a heterogeneous set of drugs can mediate the
same disease syndrome. Evidence has accumulated that drugs are transformed by extracellular
oxidation from reactive oxygen species and myeloperoxidase produced when neutrophils are
activated, maximizing the in situ accumulation of reactive drug metabolites within lymphoid
compartments. The metabolite of procainamide, procainamide hydroxylamine, displays diverse
biologic properties, but no apparent autoimmune effect has been observed. However, when
procainamide hydroxylamine was introduced into the thymus of young adult normal mice, a delayed
but robust autoimmune response developed. Disruption of central T-cell tolerance by intrathymic
procainamide hydroxylamine resulted in the production of chromatin-reactive T cells that apparently
drove the autoantibody response in the periphery. Drug-induced autoantibodies in this mouse model
were remarkably similar to those in patients with procainamide-induced lupus. Therefore, this
system has considerable promise to provide insight into the initiating events in drug-induced lupus
and may provide a paradigm for how other xenobiotics might induce systemic autoimmunity. Key
words: autoantibodies, drug-induced, lupus, T cells, reactive drug metabolites, thymus. - Environ
Health Perspect 107(suppl 5):803-806 (1999).
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It has been known since the initial description
almost five decades ago ofa side effect oflong-
term medication with hydralazine (1,2) that
certain drugs have a propensity for inducing
autoantibodies and occasionally lupuslike
symptoms. Over theyears some 46 drugs have
been implicated with various degrees ofrisk in
the induction oflupuslike disease, 38 ofwhich
are currently in use. Although drug-induced
lupus is not a major clinical problem because
it can be fully cured by discontinuing use of
the medication, it is remarkable that a low
molecular weight xenobiotic has capacity to
initiate or sustain a well-defined systemic
autoimmune disease. Not only might this
phenomenon shed light on the process ofself-
/non-self-discrimination that normally oper-
ates to avoid autoimmunity, but it may offer a
paradigm on how other xenobiotics disrupt
the immune system. Drug-induced lupus
occurs in approximately 20% of patients
treated with the antiarrhythmic drug pro-
cainamide for 1-2 years, and almost all pro-
cainamide-treated patients eventually develop
particular autoantibodies, whether or not
lupuslike symptoms appear. From drugs such
as procainamide, hydralazine, and quinidine,
which have a rather high propensity of
autoimmune manifestations in response to
exposure, drug-induced lupus has become the
best-documented example ofan environmen-
tally induced autoimmune disease due to a
noninfectious agent.
The symptomology ofdrug-induced lupus
and its objective features such as autoantibodies
to chromatin-derived antigens are remarkably
similar to those ofsystemic lupus erythemato-
sus, a disease that arises spontaneously. Drug-
induced lupus does not behave like a
hypersensitivity reaction to a drug-altered self-
antigen because ofits slow kinetics (delay of
months to years from the onset ofdrug ther-
apy to the development ofautoantibodies and
clinical symptoms), correlation with drugdose,
and the inconsistent recurrence ofsymptoms
upon drug rechallenge. In contrast, drug
hypersensitivity reactions are characteristically
drug dose independent and recur immediately
after rechallenge with the inciting agent (3).
Furthermore, as discussed below, lupus-
inducing drugs are heterogeneous, with no
common structural properties, specific affinity
for the targets ofautoantibodies, or capacity to
enhance or inhibitautoantibody binding.
In trying to understand the mechanism
underlying this phenomenon, it is important to
recognize that a wide range oftherapeutic pur-
poses are encompassed by drugs having lupus-
inducing potential. Although some ofthese
drugs are aromatic amines, there is no pharma-
cologic, chemical, or therapeutic feature that
links drugs with the capacity to induce lupus-
like disease. Yet symptoms ofarthralgias, myal-
gias, and constitutional symptoms such as
fever, weight loss, and fatigue are generally not
drug specific, and the specificities ofautoanti-
bodies induced are essentially the same regard-
less ofthe inciting agent. Therefore, it is likely
that the underlying immune perturbations
responsible for lupus induced by all drugs are
similar, leaving as enigmatic how a hetero-
geneous collection ofxenobiotics can act
through an apparentlycommon mechanism.
Neutrophil-Mediated Metabolism of
Lupus-InducingDrugs
Drug-induced lupus is a type B adverse drug
reaction (4) that cannot be predicted from the
drug's known pharmacology. One way such
idiosyncratic drug reactions can occur is
through the in vivo generation of drug
metabolites displaying new properties.
Hepatic drug metabolism is well established,
and the phase 1 reactions mediated by the
microsomal monooxygenase system and cer-
tain esterases can produce reactive compounds
substantially different from the parent drug.
Incubation ofprocainamide with human or
rat liver microsomes that contain the mixed-
function oxidases results in the formation of
an unstable product, procainamide hydroxy-
lamine (PAHA) (5,6). PAHA can be detected
after the perfusion of rat liver with pro-
cainamide in a blood-free environment (7).
Hydralazine and isoniazid are also susceptible
to hepatic oxidative metabolism (8,9). PAHA
is taken up by erythrocytes, and oxyhemo-
globin enhances its biologic activity (7,10),
presumably by converting PAHA to nitroso-
procainamide (11,12). Together with the
demonstration that rats treated with pro-
cainamide had increased liver lipid peroxide
levels and antioxidant activity (13), hepatic
metabolism oflupus-inducing drugs demon-
strates that their chemistry is compatible with
the in vivogeneration ofreactive drug metabo-
liteswith potentially newbiologic properties.
Despite the probable importance ofdrug
metabolism in the etiology ofdrug-induced
lupus, it is doubtful that liver-mediated drug
transformation is important for the following
reasons: a) hepatotoxicity is notassociated with
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drug-induced lupus; b) liver-generated
xenobiotic metabolites typically bind to micro-
somes or macromolecules neartheir site offor-
mation and fail to be produced in sufficient
amounts to interact with in situ lymphocytes
orantigen-presenting cells ortoexittheliverin
reactive forms; c) although drug metabolites
might bind to self-antigen in the liver, lupus-
inducing drugs are very small and diverse in
chemical structure, with little common struc-
tural information to specifically interact with
the chromatin-derived targets that characterize
the autoimmune response in drug-induced
lupus (see "Role ofT Cells in Drug-Induced
Lupus"). Therefore, if in vivo metabolism is a
prerequisite for initiating drug-induced lupus,
an extrahepatic process may be involved in
which reactive metabolites are generated
within an immune compartment where they
can acton the cellular elements ofthe immune
system to prevent orbreak tolerance.
Using procainamide as the prototype, we
were the first to report that activated periph-
eral blood neutrophils have capacity to metab-
olize procainamide to PAHA (14); the role of
the respiratory burst and degranulation events
associated with neutrophil activation was con-
firmed (15) and analyzed in detail (16). Drug
metabolism byneutrophils occurs in the extra-
cellular environment, in which released
myloperoxidase, acting with hydrogen perox-
ide produced upon neutrophil activation,
enzymatically oxidizes copresent drugs (17).
All major pharmacologic classes oflupus-
inducing drugs have the capacity to undergo
transformation to reactive products by expo-
sure to activated neutrophils (17-21). There
is a general correlation between susceptibility
to neutrophil-mediated transformation and
propensity to induce lupus (17); chemical
analogs ofeach drug such as the non-lupus-
inducing analog ofprocainamide, N-acetyl-
procainamide, were resistant to metabolic
transformation bythis mechanism.
Metabolism of drugs by activated
neutrophils provides a mechansim for generat-
ing highly reactive metabolites directly within
lymphoid tissue, where autoimmunity presum-
ably develops. Because neutrophils are present
in high concentration in the circulation, local
production oflabile compounds can potentially
occur in any lymphoid compartment where
neutrophils have access. This process would
minimize dilution, time-dependent hydrolysis,
and circulatory distribution ofreactive metabo-
lites, thereby maximizing their biologic effect
on thetolerancestatus oflymphocytes.
BiologicProperties ofReactive
Mtabolites of alupusInducingDrugs
Reactive intermediates of procainamide
(11,22), hydralazine (23-25), chlorpro-
mazine (18), and isoniazid (9) show capacity
to covalentlybind proteins nonspecifically and
kill a wide variety of cells under certain
in vitro conditions at pharmacologically rele-
vant concentrations (10,12,17,26). PAHA
has also been reported to be slightly mitogenic
for human lymphocytes (10). Other biologic
properties have been demonstrated for PAHA
including enhancing reactive oxygen species
production by murine macrophage (27) and
human neutrophils (10) and generating
PAHA-specific murine T cells in vivo (28).
The chemical reactivity, cytotoxicity, and
immunogenicity ofPAHA reflect the highly
reactive nature ofdrug metabolites in general;
however, none ofthese effects can be directly
related to the singular property ofthese drugs
to induce autoimmunity, as none ofthe afore-
mentioned biologic effects ofdrug metabolites
indude autoimmune features. In addition, in
vivo administration ofPAHA into the spleen
or in other peripheral sites and adoptive trans-
fer ofsyngeneic splenocytes treated ex vivo
with PAHAfailed to induce autoantibodies.
RoleofTCells inDug-InducedLupus
The hallmark ofdrug-induced lupus is the
appearance ofautoantibodies to the (H2A-
H2B)-DNA subunit ofchromatin. However,
just as with protective immunity, appearance
ofsuch IgG antibodies to selfrequires the par-
ticipation ofcognate T-cell help. T cells are
generated in the thymus and are normally tol-
erant to selfbecause differentiation and devel-
opment ofT cells in the thymus is linkedwith
a process that prevents autoreactivity-central
T-cell tolerance. In contrast, peripheral toler-
ance refers to other mechanisms employed by
T cells for avoiding autoreactivity after they
develop to maturity in the thymus. For exam-
ple, when peripheral T cells become activated
upon recognition ofan antigen in the form of
a peptide bound to the major histocompatibil-
ity complex, they undergo clonal expansion.
However, the extent ofcell division is limited
by a process called activation-induced cell
death, which can be a consequence of
enhanced expression ofthe membrane protein
Fas and its ligand whose interaction triggers
apoptosis. As a result, most ofthe progeny of
theTcelldisappear, and itisgenerallybelieved
that autoreactive T cells that happen to avoid
central cell tolerance are usually killed by this
peripheral tolerance mechanism.
Conceptually, autoimmunity is the
converse ofimmune self-tolerance, so ifdrugs
reverse ("break") tolerance ofmaturelympho-
cytes or prevent establishment of self-
tolerance during lymphocyte development,
autoimmunity might be the consequence.
Therefore, lupus-inducing drugs could act
either by breaking tolerance ofperipheral
T cells to self-antigens or preventing acquisi-
tion ofself-tolerance during T-cell develop-
ment in the thymus. Breaking peripheral
T-cell tolerance occurs upon in vitro treat-
ment ofsyngeneic-activated splenocytes,
resulting in an interestinglupuslikepathology
including autoantibodies and glomeru-
lonephritis (29,30). These phenomena
appear similar to the autoimmune side effects
accompanying the graft-versus-host reaction
upon adoptive transfer ofsemiallogeneic T
cells (31). However, drug-induced lupus has
much more limited hyperimmune features
than theglobalperturbationscharacteristicofa
graft-versus-host reaction, suggesting that if
loss ofperipheral T-cell tolerance is involved in
drug-induced lupus, it is operating on a sus-
ceptible or primed population ofautoreactive
Tcells that arosebysomeothermechanism.
The possibility that failure of central
T-cell tolerance might initiate drug-induced
lupus has been generally ignored because it is
widely assumed that the bulk ofthe T-cell
repertoire is created before birth or soon
thereafter. In contrast, drug-induced lupus
typically occurs in individuals > 50 years of
age, the age group most likely to be treated
with drugs with a propensity to induce lupus.
However, asystematic reevaluation ofthymus
structure during aging has revealed that
thymic involution and replacement oflym-
phocytic with adipose tissue starts soon after
birth and continues at a steady rate ofonly
approximately 3% per year until middle age,
when loss oflymphoid tissue slows down to
< 1% a year (32). As summarized in Table 1,
Table 1. Evidenceforthymic function in the adult.
Structural Functional
Mouse Lymphocytic islands in theaged thymus Reconstitution oftheVp repertoire afterbone
exhibit aT-cell subsetdistribution similar marrowtransplantation in irradiated old
to theyoung thymus (33) mice(34)
Production of mature Tcells denovo
from mice>1 yearofage(35)
Positive and negative selection were
retained despite thymic involution (36)
Human Lymphocytic islands in the aged thymus NaiveT-cell subsets are generated de novo
exhibit aT-cell subset distribution similar fromtransplanted bone marrow or peripheral
to the youngthymus(37) stem cells aftermyelosuppression (38)
DNA excision circles characteristic ofnewly
formed Tcells are detected inthe circulation
only in nonthymectomized elderly people (39).
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there is a growing body ofevidence in the
mouse and human that the thymus functions
in the adult to produce mature T cells.
Therefore, the machinery for preserving
T-cell tolerance by this central immune organ
must be maintained throughout life, and
interference with this process by drugs could
result in autoimmunity.
Disuption ofCentralT-CellTolerance
Causes Lupus-LikeAutoimmunity
To determine whether disruption ofcentral
T-cell tolerance by lupus-inducing drugs
could result in autoimmunity, PAHA was
injected into the thymus of young adult
(C57BL/6xDBA/2)F1 mice. Two intra-
thymic injections with the drug resulted in
the rapid appearance ofIgM anti-denatured
DNA antibodies, followed by a delayed but
sustained production ofIgG antichromatin
antibodies (Figure 1) (40). Specificity, inhibi-
tion, and blocking studies demonstrated that
the serology of PAHA-treated mice had a
striking resemblance to that ofpatients with
procainamide-induced lupus, suggesting that
the immune system had undergone similar
perturbations in both species (Figure 2). In
the peripheral immune organs such as the
spleen and lymph nodes of PAHA-treated
mice, chromatin-reactive T cells were detected
at a time point when antichromatin antibod-
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ies started to rise (40), suggesting that PAHA
action in the thymus resulted in the export of
autoreactive T cells to the periphery where
they provided T-helper cell function to B cells
with potential to produce autoantibodies.
Adoptive transfer of PAHA-induced
chromatin-reactive T cells into otherwise
untreated mice was sufficient to induce an
autoantibody response (41). However, rela-
tively large numbers ofchromatin-reactive
T cells were required to elicit an IgG anti-
chromatin response, whereas adoptive transfer
ofless than 5 million T cells resulted in a
much more restricted immune response
(Table 2). These observations, together with
the finding that two intrathymic injections
were required to induce IgG antichromatin
antibodies, suggested that peripheral tolerance
mechanisms were limiting the capacity of
chromatin-reactive T cells to provide helper
function for B cells. Antichromatin antibodies
developed after a single intrathymic PAHA
injection into the Fas-deficient C57BL/6-
lpr/lpr mice (41), suggesting that Fas-
mediated activation-induced cell death was
responsible for limiting autoimmunity in nor-
mal mice. However, as demonstratedwith two
intrathymic PAHA injections or by adoptive
transfer oflarge numbers ofchromatin-reactive
T cells in Fas-intact mice, peripheral tolerance
mechanisms fail to prevent autoimmunity in
normal mice when the immune system is
subjected to a heavy load or second wave of
chromatin-reactive T cells. Therefore,
although defective activation-induced lym-
phocyte death (41) or drug-induced graft-
versus-hostlike syndrome (29,30) might
accelerate autoimmune disease, it appears that
repetitive emigration ofautoreactive T cells
from the thymus is sufficient to initiate and
sustain systemic autoimmunity.
Presently there is no evidence that drug-
induced lupus in humans is initiated when
central T-cell tolerance is disrupted by the
action of reactive drug metabolites in the
thymus. The most compelling argument that
the thymus is the critical target ofxenobiotic
action is a) this organ is the only site in the
mouse where PAHA presence initiates
systemic autoimmunity and b) the specificity
of PAHA-induced autoantibodies in the
mouse is very similar to those in patients
with drug-induced lupus. It is possible that
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Figure 1. Serum autoantibody after intrathymic injection of PAHA. Abbreviations: anti-dDNA, anti-denatured DNA;
OD, optical density; PAHA, procainamide hydroxylamine. Eleven (C57BL/6 x DBA/2)F1 mice received two intrathymic
injections of 4 mM PAHA 2 weeks apart. Seven control mice were injected with phosphate-buffered saline. IgG anti-
body activity to chromatin (solid lines) and IgM anti-dDNA antibody(dashed lines) were determined byenzyme-linked
immunosorbent assay in serial serum samples of individual mice represented by unique symbols. IgM anti-dDNA
activity in a typical control mouse is shown (open circles). Reprinted from Kretz-Rommel et al. (40), with permission
of the JoumalofClinicalInvestigation.
Figure 2. Inhibition of PAHA-induced antichromatin activ-
ity by (H2A-H2B)-DNA in a competition assay.
Abbreviation: PAHA, procainamide hydroxalamine. The
capacity to bind chromatin of IgG in 1:200 diluted sera of
two (C57BL/6 x DBA/2)F1 mice subjected to two
intrathymic PAHA injections ( ) or of two patients
with procainamide-induced lupus (-------) was measured in
the presence of increasing amounts of soluble (H2A-H2B)-
DNA. Reprinted from Kretz-Rommel et al. (40), with
permission ofthe JournalofClinicalInvestigation.
Table 2. Antibody activity in the serum of (C57BL/6 x
DBA/2)Fi mice after adoptive transfer of chromatin-
reactive Tcells.a
Number ofT cells IgM anti-dDNA IgG antichromatin
transferred at 1 week at 3 weeks
(3 mice/group) (mean OD± SD) (mean OD± SD)
500 0.189± 0.074 0
5,000 0.575 ± 0.450 0
50,000 0.618 ± 0.302 0
500,000 0.347± 0.143 0.201 ± 0.348
5,000,000 0.963 ± 0.738 0.324 ± 0.057
Abbreviations: anti-dDNA, anti-denatured DNA; OD, optical den-
sity; SD, standard deviation. "Data from Kretz-Rommel et al. (41).
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people with more active thymic function are
particularly vulnerable to disruption ofcen-
tral cell tolerance by reactive drug metabo-
lites, and demonstration ofsuch a correlation
should add considerable weight to the
importance ofthis mechanism.
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